Mark J Smyth1, Jeremy Swann, Erika Cretney
1Cancer Immunology Program, Trescowthick Laboratories, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia. mark.smyth@petermac.org
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
The NKG2D receptor is crucial for controlling new tumor formation. Blocking NKG2D increases susceptibility to methylcholanthrene-induced fibrosarcoma, highlighting its role in early cancer protection.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: